TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17604004
Drug: Pergolide (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.125 mg) before 1 Hz rTMS
Study: 17604004
Drug: Pergolide (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.125 mg) before sham rTMS
Study: 16427122
Drug: Silane treatment
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silane treatment (Monobond S, Ivoclar Vivadent)
Study: 16427122
Drug: No silane
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: No silane treatment
Study: 9894381
Drug: Prophylactic antiarrhythmic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antiarrhythmic therapy
Study: 7878805
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) as an adjunct to cyclosporine-based immunosuppression
Study: 1973942
Drug: Gepirone (5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone (5-30 mg/day)
Study: 1973942
Drug: Gepirone (continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone (continuation therapy after 6 weeks of open therapy)
Study: 28740085
Drug: Alcohol self‐dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol self‐dosing
Study: 19439989
Drug: Acetylcysteine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (5 g in 5% glucose in a final volume of 50 ml) administered intravenously during hemodialysis
Study: 7714222
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day buspirone
Study: 2655688
Drug: ICI 169,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 169, 369 (10, 30, and 50 mg)
Study: 29173304
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg/dose, 2 doses)
Study: 29173304
Drug: Prednisolone/prednisone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone/prednisone (1.5 mg/kg/d for 1 day, followed by 1 mg/kg/d on days 2‐5)
Study: 25537065
Drug: Sport goggles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sport goggles (G)
Study: 21349458
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + glycoprotein IIb/IIIa inhibitor
Study: 17209059
Drug: 6 weekly
Normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weekly 2-CdA infusions
Study: 16942627
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) twice daily sessions
Study: 16942627
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) once daily sessions
Study: 8754291
Drug: FMLP solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMLP solution
Study: 1941404
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus infusion of 10% calcium gluconate
Study: 1941404
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus infusion of 5% calcium gluconate
Study: 1941404
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus infusion of calcium gluconate (both 5% and 10%)
Study: 7009993
Drug: Intrapleural BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural BCG immunotherapy
Study: 28407726
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) plus active Attention Bias Modification Therapy (ABMT)
Study: 28407726
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) plus placebo Attention Bias Modification Therapy (ABMT)
Study: 26329852
Drug: Pre-cooling for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-cooling for 2 min before plain lidocaine injection
Study: 26329852
Drug: Buffered lidocaine
Normalized name: buffered lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered lidocaine injection
Study: 24009042
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 mg)
Study: 20972299
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of antibiotics (48 to 96 hours)
Study: 20972299
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of antibiotics
Study: 19260871
Drug: FENO guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENO guided therapy
Study: 19260871
Drug: Standard asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard asthma therapy
Study: 15479681
Drug: Prebiotic carbohydrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic carbohydrates (7.5 g of oligofructose and 7.5 g inulin)
Study: 11777121
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy (SEG)
Study: 7951548
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) treatment in untreated patients with low thyroid CT number
Study: 7951548
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) treatment in patients with normal thyroid CT number prior to therapy
Study: 3038156
Drug: Oral nafazatrom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nafazatrom (Bay g6575, 2 X 3 g)
Study: 31811542
Drug: Myofunctional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofunctional therapy support program (MTSP) for 12 weeks
Study: 31811542
Drug: One education
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One education session of myofunctional therapy (control)
Study: 22867771
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections of insulin (MDI)
Study: 21982167
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol and remifentanil (PR group)
Study: 15680096
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (open reduction and internal fixation using a standard lateral approach)
Study: 15680096
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (ice and elevation)
Study: 12067850
Drug: DCA infusion
Normalized name: DCA
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCA infusion (100 mg/kg body wt)
Study: 12067850
Drug: Control (normoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normoxic breathing and saline infusion)
Study: 9876731
Drug: Nizatidine 100
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine 100 mg intravenously
Study: 7900703
Drug: Continuous fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous fluorouracil infusion (FUcont)
Study: 2612552
Drug: Predictive warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive warfarin maintenance dosing technique
Study: 2612552
Drug: Empirical dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical dosing method
Study: 11938803
Drug: Chinese drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drugs (CD) for invigorating Spleen to remove dampness, activating blood circulation to eliminate Turbid
Study: 1383924
Drug: MOP chemotherapy
Normalized name: methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MOP chemotherapy
Study: 1383924
Drug: MOP/ABVD chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOP/ABVD chemotherapy
Study: 3905463
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg) in addition to routine insulin treatment
Study: 25486269
Drug: Levodopa equivalent
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa equivalent daily dose
Study: 25481367
Drug: Caffeine administration
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine administration (conditional vs deceptive)
Study: 23560727
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily for 1 week
Study: 21493022
Drug: Estrogen therapy-control
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy-control (ET-CO)
Study: 19820441
Drug: Natalizumab induction
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab induction therapy (12 weeks)
Study: 19820441
Drug: Natalizumab maintenance
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab maintenance therapy (48 weeks post-induction)
Study: 9336321
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alcohol (0.8 g/kg) and cocaine (100 mg)
Study: 9336321
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alcohol and cocaine
Study: 2879734
Drug: Urapidil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 15 mg i.v.
Study: 2879734
Drug: Urapidil 30
Normalized name: urapidil 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 30 mg i.v.
Study: 2879734
Drug: Propranolol 5
Normalized name: propranolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 5 mg i.v. (positive control)
Study: 26665553
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL) alone
Study: 26665553
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Intravitreal bevacizumab + macular photocoagulation)
Study: 12927315
Drug: estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol 2 mg/day + cyproterone acetate 1 mg/day in a cyclic sequential regimen
Study: 12927315
Drug: estradiol hemihydrate
Normalized name: Estradiol hemihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol hemihydrate 2 mg/day plus norethisterone acetate (NETA) 1 mg/day in a continuous combined regimen
Study: 12927315
Drug: estradiol hemihydrate
Normalized name: Estradiol hemihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol hemihydrate 1 mg/day plus NETA 0.5 mg/day in a continuous combined regimen
Study: 11009230
Drug: Oral mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mexiletine (up to 900 mg/d)
Study: 8725471
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (160 mg per day in two divided doses)
Study: 28404110
Drug: Ombitasvir (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombitasvir (25 mg), paritaprevir (150 mg), ritonavir (100 mg) plus weight-based ribavirin for 12 weeks
Study: 24965536
Drug: Catumaxomab plus
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catumaxomab plus prednisolone (25 mg intravenous premedication)
Study: 22692377
Drug: S-ketamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (20 mg/h for 2 h)
Study: 18506154
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg daily (n = 29)
Study: 18506154
Drug: AEGR-733 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEGR-733 5.0 mg daily for the first 4 weeks, 7.5 mg daily for the second 4 weeks, and 10 mg daily for the last 4 weeks (n = 28)
Study: 18506154
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg daily and AEGR-733 with dose titration (n = 28)
Study: 9712245
Drug: Specialists in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialists in gastrointestinal medicine
Study: 7749424
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg body weight)
Study: 28681744
Drug: Maintained levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maintained levodopa dose (Group 1, n = 66)
Study: 28681744
Drug: Reduced levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reduced levodopa dose by 15-25% (Group 2, n = 41)
Study: 28681744
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after LCE administration
Study: 24366725
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 0.5% (15 mg test dose + 50 mg)
Study: 23031632
Drug: Silymarin cream
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin cream (0.1) applied twice daily for 4 weeks
Study: 23031632
Drug: Silymarin cream
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin cream (0.2) applied twice daily for 4 weeks
Study: 23417317
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 4 weeks
Study: 20415160
Drug: Self-controlled concurrent
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-controlled concurrent feedback
Study: 20415160
Drug: Imposed concurrent
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imposed concurrent feedback (yoked group)
Study: 20415160
Drug: No concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concurrent feedback (control group)
Study: 15356071
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (transdermal estradiol 50 microg and micronized progesterone 100 mg/d)
Study: 11594636
Drug: Balance training
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance training in group, twice a week for eight weeks
Study: 2675962
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + CS + CL
Study: 2675962
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + CL
Study: 2675962
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + CS + CO + CL
Study: 9062854
Drug: G
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G
Study: 28386739
Drug: Articaine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 60 mg with fentanyl 10 µg (group AF10)
Study: 28386739
Drug: Articaine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 60 mg with fentanyl 20 µg (group AF20)
Study: 28386739
Drug: Plain articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain articaine 60 mg with saline (group AF0)
Study: 28386739
Drug: Fentanyl 20
Normalized name: fentaNYL 200 mcg buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 20 µg (group AF20)
Study: 25361738
Drug: Heparin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin treatment in Han patients
Study: 23836249
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 80 mg tobramycin twice daily for 12 months
Study: 15533901
Drug: Soy intervention
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy intervention (two daily servings of soy foods containing approximately 50 mg of isoflavones)
Study: 11533326
Drug: Single-dose ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ferrous sulfate drops (40 mg elemental iron once daily)
Study: 11533326
Drug: 3-times-daily ferrous
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-times-daily ferrous sulfate drops (40 mg elemental iron total per day)
Study: 11533326
Drug: Single-dose ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ferrous sulfate drops
Study: 11533326
Drug: 3-times-daily ferrous
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-times-daily ferrous sulfate drops
Study: 2223330
Drug: Alfentanil 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 50 micrograms kg‐1 followed by an infusion of 50 micrograms kg‐1 h‐1 and propofol infusion
Study: 2223330
Drug: Clonidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.6 mg added to premedication
Study: 6989245
Drug: Multidose intravenous
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose intravenous sodium cephalothin
Study: 6989245
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous sodium cephalothin
Study: 6989245
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral metronidazole
Study: 31407871
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tadalafil orally once daily for 12 weeks
Study: 28583031
Drug: Bortezomib dose
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib dose intensity ≥4.6 mg/m2/cycle
Study: 28583031
Drug: Bortezomib dose
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib dose intensity <4.6 mg/m2/cycle
Study: 25456560
Drug: Single ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of 3.7 to 55.7 mg of samidorphan
Study: 25456560
Drug: Multiple ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of 10 or 20 mg of samidorphan for 7 days
Study: 19755964
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group A (immunosuppressed patients)
Study: 19755964
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group B (non-immunosuppressed patients)
Study: 19755964
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group C (healthy controls)
Study: 19755964
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with 23-valent pneumococcal polysaccharide vaccines (PSVs) in Group A
Study: 18616088
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 20 mg cinnarizine and 40 mg dimenhydrinate (one tablet three times daily) for 4 weeks
Study: 18616088
Drug: Betahistine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (12 mg betahistine dimesylate, one tablet three times daily) for 4 weeks
Study: 18616088
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of 20 mg cinnarizine and 40 mg dimenhydrinate
Study: 16139582
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation plus treatment as usual (VNS+TAU)
Study: 3971683
Drug: Oral narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral narcotic analgesics plus ibuprofen 400 mg four times daily
Study: 3971683
Drug: Oral narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral narcotic analgesics alone (placebo)
Study: 29741912
Drug: Standardized capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized capsules of Stachys lavandulifolia
Study: 17647055
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of chili powder along with antibiotics and analgesics
Study: 17647055
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and analgesics alone
Study: 15999594
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy alone or in combination with hormone therapy
Study: 15999594
Drug: Standard hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hormone therapy
Study: 15999594
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy and chemotherapy
Study: 9859533
Drug: Cefoxitin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 3 x 1 g (14 subjects)
Study: 9859533
Drug: Cefotetan 2
Normalized name: cefotetan 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 2 x 1 g (43 subjects)
Study: 9859533
Drug: Cefalotin 3
Normalized name: Céfalotine
DrugBank: Cefalotin (DB00456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefalotin 3 x 2 g for 24 hours (27 subjects)
Study: 9859533
Drug: Cefalotin 3
Normalized name: Céfalotine
DrugBank: Cefalotin (DB00456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefalotin 3 x 2 g for 72 hours (41 subjects)
Study: 7881264
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CyA) mouthwash, 5 ml solution at 10% in olive oil, used for five minutes, three times a day for eight weeks.
Study: 7881264
Drug: Acetonide of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetonide of triamcinolone 01% in aqueous solution (control group).
Study: 1983349
Drug: Intravenous pentagastrin
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentagastrin (0.6 microgram.kg/h) with placebo